Schill W B, Rjosk H K, Krizić A
Hautarzt. 1980 Apr;31(4):191-7.
31 men with idiopathic oligozoospermia and 23 men with idiopathic asthenozoospermia were treated three months by oral administration of daily 600 units kallikrein. In a greater number of patients apart from the semen analysis different seminal plasma proteins and enzymes as well as hormones in serum (LH, FSH, prolactin, testosterone) and in seminal plasma (LH, prolactin) were determined. There was a significant increase of sperm count and sperm motility in the oligozoospermic group. In asthenozoospermic patients sperm motility was significantly increased, however, sperm count decreased within the normal range. Conception rate was 25% in the oligozoospermic goup and 36% in the asthenozoospermic group. A treatment period of three months showed better results than seven weeks and a dosage of 600 units kallikrein daily was significantly better than daily 300 units. During kallikrein therapy mean concentrations of alpha U,x-antichymotrypsin in seminal plasma and serum LH, prolactin and testosterone increased significantly. Seminal plasma levels of LH and prolactin remained unchanged. The mode of action of systemic kallikrein therapy may be at the level of tissue hormones (kinin liberation), however, an increase of the intratesticular testosterone level and an interference with the blood-seminal plasma barrier has also to be considered.
31名特发性少精子症患者和23名特发性弱精子症患者口服每日600单位激肽释放酶，治疗三个月。除精液分析外，还对更多患者测定了不同的精浆蛋白、酶以及血清（促黄体生成素、促卵泡生成素、催乳素、睾酮）和精浆（促黄体生成素、催乳素）中的激素。少精子症组的精子数量和精子活力显著增加。在弱精子症患者中，精子活力显著提高，然而精子数量在正常范围内下降。少精子症组的受孕率为25%，弱精子症组为36%。三个月的治疗期比七周的效果更好，每日600单位激肽释放酶的剂量明显优于每日300单位。在激肽释放酶治疗期间，精浆中α1抗胰凝乳蛋白酶以及血清促黄体生成素、催乳素和睾酮的平均浓度显著增加。精浆中促黄体生成素和催乳素水平保持不变。全身性激肽释放酶治疗的作用方式可能在组织激素水平（激肽释放），然而，也必须考虑睾丸内睾酮水平的增加以及对血-精浆屏障的干扰。
